Company Encyclopedia
View More
name
GENFLEET-B
02595.HK
GenFleet Therapeutics (Shanghai) Inc. operates as a biopharmaceutical company that focuses on developing novel treatment options in the fields of oncology that cover different lines of treatments of multiple solid tumors, as well as autoimmune and inflammatory diseases. The company’s products include GFH925, help for the treatment of advanced non-small cell lung cancer, and GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C. The company was incorporated in 2017 and is based in Shanghai, China.
1.428 T
02595.HKMarket value -Rank by Market Cap -/-

Financial Score

13/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking0/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE41.40%A
    • Profit Margin-647.20%E
    • Gross Margin80.81%A
  • Growth ScoreB
    • Revenue YoY39.97%A
    • Net Profit YoY-31.41%D
    • Total Assets YoY9.45%B
    • Net Assets YoY-43.61%E
  • Cash ScoreB
    • Cash Flow Margin-15.45%D
    • OCF YoY39.97%A
  • Operating ScoreD
    • Turnover0.18D
  • Debt ScoreE
    • Gearing Ratio422.38%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Top 10 HK Stock Losers (10.24)

    SHANDONG MOLONG(00568) fell 15.71%, with a trading turnover 787.2 Million HKD, and a year-to-date rose 250.4%. TIANJIN CAPITAL(01065) fell 11.27%, with a trading turnover 166.0 Million HKD, and a year-to-date rose 38.1%. QHD PORT(03369) fell 10.76%, with a trading turnover 109.4 Million HKD, and a year-to-date rose 34.1%.

    LB Select·
    HK
    00568
    -0.47%
    HK
    01065
    -0.45%
    HK
    03369
    -0.36%
    LB Select·
    HK
    00568
    -0.47%
    HK
    01065
    -0.45%
    HK
    03369
    -0.36%

    Top 10 HK Stock Gainers (10.23)

    TIANJIN CAPITAL(01065) rose 24.17%, with a trading turnover 531.6 Million HKD, and a year-to-date rose 55.7%. IB SETTLEMENT(00147) rose 15.38%, with a trading turnover 11.6 Million HKD, and a year-to-date rose 206.8%. CHINA HK POWER(00931) rose 14.75%, with a trading turnover 50.5 Million HKD, and a year-to-date rose 89.2%.

    LB Select·
    HK
    01065
    -0.45%
    HK
    00147
    -2.06%
    HK
    00931
    -1.89%
    LB Select·
    HK
    01065
    -0.45%
    HK
    00147
    -2.06%
    HK
    00931
    -1.89%

    Understanding the Market | GENFLEET-B turns from decline to rise of over 9%, first patient enrolled in the study of GFH375 combination therapy for advanced solid tumors completed

    GENFLEET-B's stock price turned from decline to increase in the afternoon, with an increase of over 9%. As of the time of publication, the stock price rose by 6.71%, reported at HKD 28.3, with a trading volume of HKD 44.5183 million. The company announced that its KRAS G12D inhibitor GFH375 combination therapy has completed the enrollment of the first patient at Peking University Cancer Hospital, with the study approved by the National Medical Products Administration, involving combination with cetuximab or chemotherapy. The efficacy and safety of GFH375 will be reported at the 2025 ESMO Annual Meeting

    Zhitong·
    HK
    02595
    +4.80%
    Zhitong·
    HK
    02595
    +4.80%

    Top 10 HK Stock Losers (10.22)

    E&P GLOBAL(01142) fell 11.2%, with a trading turnover 46.7 Million HKD, and a year-to-date rose 239.7%. JST GROUP(06687) fell 10.08%, with a trading turnover 292.1 Million HKD, and a year-to-date rose 11.4%. GENFLEET-B(02595) fell 9.73%, with a trading turnover 58.4 Million HKD, and a year-to-date rose 30.1%.

    LB Select·
    HK
    01142
    -7.55%
    HK
    06687
    -3.39%
    HK
    02595
    +4.80%
    LB Select·
    HK
    01142
    -7.55%
    HK
    06687
    -3.39%
    HK
    02595
    +4.80%

    GENFLEET-B: The first patient has been dosed in the Phase Ib/II study of KRAS G12D inhibitor GFH375 in combination with cetuximab or chemotherapy for the treatment of advanced solid tumors

    GENFLEET-B announced that the first patient has been dosed in the Phase Ib/II study of GFH375 in combination with cetuximab or chemotherapy, targeting KRAS G12D mutant advanced solid tumors. The study received clinical trial approval in September and primarily evaluates the safety, tolerability, and efficacy of the therapy. The monotherapy of GFH375 is expected to enter Phase I/II trials in 2024 and has received FDA Fast Track designation

    Zhitong·
    HK
    02595
    +4.80%
    Zhitong·
    HK
    02595
    +4.80%
    Posts
    View More

    $GENFLEET-B(02595.HK) The recent Longbridge lottery rate is acceptable 😌

    • 0